• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Renal artery denervation is effective and well-tolerated for blood pressure reduction

byJessie WillisandTeddy Guo
November 2, 2022
in Cardiology, Chronic Disease, Nephrology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients assigned to renal artery denervation had significantly lower office and ambulatory blood pressures at 36-month follow-up compared to sham control.

2. Renal artery denervation was well-tolerated with similar rates of the composite safety endpoint at 48 months between treatment groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Hypertension is a medical condition that significantly increases the risk of other diseases, including those of the heart, brain and kidney. The SYMPLICITY HTN-3 trial evaluated the use of renal artery denervation for the management of treatment-resistant hypertension. Participants were randomly assigned to either treatment (renal artery denervation) or sham control, with the option of being included in a crossover group after 6 months. After 36 months, renal artery denervation significantly reduced systolic blood pressure, both in-office and ambulatory, compared to sham control. Renal artery denervation additionally significantly increased time in the therapeutic window compared to sham control. The rate of the composite safety endpoint, including all-cause mortality, was comparable between the two groups. Limitations of this study include the smaller sham control group size considering the number of patients that crossed over. Nonetheless, this study supports the use of renal artery denervation as an effective treatment for patients sub-optimally controlled on medication.

Click to read the study in The Lancet

Relevant Reading: Assessment of long-term benefit of intensive blood pressure control on residual life span: secondary analysis of the systolic blood pressure intervention trial (SPRINT)

In-Depth [randomized controlled trial]: SYMPLICITY HTN-3 was a randomized controlled trial conducted across 88 centres in the USA. Eligible patients were aged 18 to 80 years with treatment-resistant hypertension (office systolic blood pressure > 160 mm Hg or 24 h ambulatory systolic blood pressure > 135 mm Hg) on three or more drugs including a diuretic. A total of 535 enrolled patients were randomly assigned 2:1 to receive either renal artery denervation or sham control. The mean age of the participants was 57.9 years and 61% were men. The primary endpoint was the change in office systolic blood pressure at 6 months. After 6 months, patients were unmasked, and eligible participants who had received the sham control were offered cross over to receive renal artery denervation. After 36 months, the change in office systolic blood pressure was -26.4 mm Hg in the treatment group and -5.7 mm Hg in the sham control group (adjusted treatment difference -22.1 mm Hg [95% CI -27.2 to -17.0]; p < 0.0001). At the same time point, the change in ambulatory systolic blood pressure was -15.6 mm Hg in the treatment group and -0.3 mm Hg in the sham control group (adjusted treatment difference -16.5 mm Hg [-20.5 to -12.5]; p < 0.0001). Time spent in therapeutic blood pressure range was also significantly higher in the treatment group compared to control (p < 0.0001). There were no late-emerging complications from renal artery denervation. The rate of the composite safety endpoint at 48 months was 15% for the treatment group, 14% for the crossover group, and 14% for the non-crossover group.

RELATED REPORTS

#VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension

#VisualAbstract: Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

Extracorporeal CPR and conventional CPR similarly improve cardiac arrest survival

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: blood pressureblood pressure controlcardiologycardiovascular diseasecardiovascular healthHigh Blood Pressurehypertensionrenal artery denervationrenal denervationresistant hypertension
Previous Post

Endovascular therapy associated with slightly improved outcomes in acute stroke patients with distal medium vessel occlusion compared with medical management

Next Post

In-person follow-ups better superior to telehealth for preventing repeated hospital presentation following emergency department visits

RelatedReports

#VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
StudyGraphics

#VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension

February 3, 2023
#VisualAbstract: Aspirin thromboprophylaxis noninferior to low-molecular-weight heparin in patients with fractures
StudyGraphics

#VisualAbstract: Catheter ablation reduces rates of persistent atrial fibrillation and atrial tachyarrhythmia

February 3, 2023
Antiarrhythmic drugs have no survival benefit in shock-refractory out-of-hospital cardiac arrest
Cardiology

Extracorporeal CPR and conventional CPR similarly improve cardiac arrest survival

February 2, 2023
Few older adolescents meet recommended levels of physical activity
Wellness

Wellness Check: Exercise

February 2, 2023
Next Post
Steroids and opioids often inappropriately prescribed in the emergency department for pediatric pneumonia and sinusitis

In-person follow-ups better superior to telehealth for preventing repeated hospital presentation following emergency department visits

Quick Take: Effect of Developmentally Adapted Cognitive Processing Therapy for Youth With Symptoms of Posttraumatic Stress Disorder After Childhood Sexual and Physical Abuse

Wellness Check: Mental Health

The 2 Minute Medicine Podcast Episode 1

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Concordance of diagnosis of autism spectrum disorder made by pediatricians vs multidisciplinary specialist teams
  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options